StockNews.com Lowers Corvus Pharmaceuticals (NASDAQ:CRVS) to Sell

Corvus Pharmaceuticals (NASDAQ:CRVS) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Separately, LADENBURG THALM/SH SH boosted their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.83.

Corvus Pharmaceuticals Price Performance

Shares of Corvus Pharmaceuticals stock opened at $5.81 on Friday. Corvus Pharmaceuticals has a one year low of $1.05 and a one year high of $6.15. The firm has a market capitalization of $363.42 million, a price-to-earnings ratio of -11.17 and a beta of 1.14. The business has a 50-day simple moving average of $4.57 and a 200 day simple moving average of $2.85.

Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its earnings results on Tuesday, August 6th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05. During the same period in the prior year, the business earned ($0.14) earnings per share. On average, sell-side analysts expect that Corvus Pharmaceuticals will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $44,000. Marshall Wace LLP acquired a new position in Corvus Pharmaceuticals during the 2nd quarter valued at about $136,000. Avity Investment Management Inc. boosted its stake in Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock valued at $146,000 after purchasing an additional 16,000 shares during the last quarter. Towerview LLC boosted its stake in Corvus Pharmaceuticals by 4.6% during the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock valued at $728,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in Corvus Pharmaceuticals by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after purchasing an additional 142,724 shares during the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.